Tricida is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, Veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI) tract. Veverimer is a non-absorbed, low-swelling, spherical polymer. It is a single, high molecular weight, crosslinked polyamine molecule. Veverimer is designed to specifically bind and remove hydrochloric acid from the GI tract. Acid binding and removal from the GI tract is an approach to treating metabolic acidosis without introducing deleterious counterions or metals. We show 20 historical shares outstanding datapoints in our coverage of TCDA's shares outstanding history.
Understanding the changing numbers of TCDA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TCDA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TCDA by allowing them to research TCDA shares outstanding history
as well as any other stock in our coverage universe. |
Free TCDA Email Alerts:
Video: Shares Outstanding Importance
